nicorandil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
nicotinic acid or nicotinoyl alcohol derivatives	1919	65141-46-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: nicorandil perisalol sigmart	A derivative of the NIACINAMIDE that is structurally combined with an organic nitrate. It is a potassium-channel opener that causes vasodilatation of arterioles and large coronary arteries. Its nitrate-like properties produce venous vasodilation through stimulation of guanylate cyclase. Molecular weight: 211.18 Formula: C8H9N3O4 CLOGP: 0.54 LIPINSKI: 0 HAC: 7 HDO: 1 TPSA: 97.04 ALOGS: -2.25 ROTB: 5

Molecule

Description

Molfile Inchi Smiles

Synonyms:

nicorandil
perisalol
sigmart

A derivative of the NIACINAMIDE that is structurally combined with an organic nitrate. It is a potassium-channel opener that causes vasodilatation of arterioles and large coronary arteries. Its nitrate-like properties produce venous vasodilation through stimulation of guanylate cyclase.

Molecular weight: 211.18
Formula: C8H9N3O4
CLOGP: 0.54
LIPINSKI: 0
HAC: 7
HDO: 1
TPSA: 97.04
ALOGS: -2.25
ROTB: 5

Drug dosage:

Dose	Unit	Route
40	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	4.20 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	4.06 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	75 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.40 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	8.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.76 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	3.60 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1984	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	66.50	25.63	75	3242	263340	63222365
Cardiac failure	59.71	25.63	44	3273	89098	63396607
Fixed eruption	46.26	25.63	11	3306	1153	63484552
Hyponatraemia	42.95	25.63	40	3277	111860	63373845
Bradycardia	35.71	25.63	30	3287	73197	63412508
Upper gastrointestinal haemorrhage	35.33	25.63	18	3299	18834	63466871
Brain stem stroke	34.14	25.63	7	3310	370	63485335
Hypotension	33.81	25.63	55	3262	272549	63213156
Drug interaction	33.67	25.63	50	3267	229081	63256624
Renal impairment	32.76	25.63	31	3286	88324	63397381
Rhabdomyolysis	32.36	25.63	23	3294	43928	63441777
Drug ineffective	31.55	25.63	8	3309	1044757	62440948
Hyperkalaemia	28.07	25.63	23	3294	54180	63431525
Large intestinal ulcer	26.40	25.63	9	3308	3435	63482270
Haemorrhage intracranial	25.69	25.63	13	3304	13406	63472299

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Interstitial lung disease	57.51	19.24	62	5706	65220	34885943
Postictal paralysis	49.90	19.24	11	5757	253	34950910
Angina pectoris	45.04	19.24	39	5729	31324	34919839
Melaena	41.00	19.24	39	5729	35341	34915822
Acute kidney injury	39.54	19.24	125	5643	304863	34646300
Cardiac failure	35.44	19.24	58	5710	91190	34859973
Drug interaction	34.32	19.24	98	5670	225848	34725315
Altered state of consciousness	31.92	19.24	28	5740	22865	34928298
Cerebral infarction	31.30	19.24	30	5738	27425	34923738
Intraventricular haemorrhage	31.11	19.24	14	5754	3517	34947646
Muscle haemorrhage	27.32	19.24	13	5755	3705	34947458
Chest pain	26.43	19.24	62	5706	126700	34824463
Pulmonary alveolar haemorrhage	26.18	19.24	16	5752	7496	34943667
Pericardial haemorrhage	26.17	19.24	12	5756	3146	34948017
Pneumonia aspiration	25.55	19.24	33	5735	41870	34909293
Hepatic function abnormal	24.07	19.24	33	5735	44330	34906833
Prerenal failure	24.05	19.24	10	5758	2074	34949089
Acute myocardial infarction	23.38	19.24	36	5732	53683	34897480
Hypomagnesaemia	23.26	19.24	23	5745	21828	34929335
Prinzmetal angina	23.07	19.24	8	5760	1011	34950152
Electrocardiogram QT prolonged	23.03	19.24	31	5737	40921	34910242
Haemorrhage subcutaneous	23.00	19.24	10	5758	2314	34948849
Coronary artery restenosis	22.96	19.24	8	5760	1026	34950137
Hypovitaminosis	22.91	19.24	7	5761	593	34950570
Bradycardia	22.84	19.24	43	5725	75375	34875788
Inappropriate antidiuretic hormone secretion	22.76	19.24	18	5750	12735	34938428
Swollen tongue	22.67	19.24	19	5749	14586	34936577
Lactic acidosis	22.17	19.24	28	5740	34744	34916419
Malaise	22.02	19.24	74	5694	185751	34765412
Hypotension	21.78	19.24	83	5685	221566	34729597
Muscle contractions involuntary	21.74	19.24	9	5759	1847	34949316
Cardiorenal syndrome	21.63	19.24	7	5761	716	34950447
Coagulation factor deficiency	21.25	19.24	5	5763	155	34951008
Photosensitivity reaction	21.19	19.24	16	5752	10578	34940585
Haemoptysis	20.45	19.24	27	5741	34979	34916184

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Acute kidney injury	98.64	19.40	199	9146	519205	79215838
Cardiac failure	80.73	19.40	95	9250	154747	79580296
Drug interaction	71.53	19.40	153	9192	415030	79320013
Interstitial lung disease	70.47	19.40	76	9269	112524	79622519
Angina pectoris	68.10	19.40	53	9292	51679	79683364
Hyponatraemia	61.29	19.40	89	9256	177759	79557284
Melaena	56.54	19.40	51	9294	60839	79674204
Cerebral infarction	56.25	19.40	45	9300	45631	79689412
Bradycardia	52.87	19.40	72	9273	135485	79599558
Postictal paralysis	49.66	19.40	11	9334	369	79734674
Upper gastrointestinal haemorrhage	49.32	19.40	40	9305	41340	79693703
Drug ineffective	43.34	19.40	38	9307	1080875	78654168
Acute myocardial infarction	43.00	19.40	49	9296	76987	79658056
Renal impairment	41.82	19.40	70	9275	157713	79577330
Hepatic function abnormal	41.65	19.40	47	9298	73060	79661983
Ischaemic stroke	41.55	19.40	33	9312	33098	79701945
Hypotension	41.13	19.40	129	9216	440188	79294855
Pneumonia aspiration	39.77	19.40	44	9301	66923	79668120
Hypomagnesaemia	37.20	19.40	36	9309	46875	79688168
Gastric ulcer	34.66	19.40	30	9315	33875	79701168
Cerebral haemorrhage	34.43	19.40	38	9307	57635	79677408
Altered state of consciousness	33.57	19.40	33	9312	43789	79691254
Intraventricular haemorrhage	31.33	19.40	14	9331	4873	79730170
Gastrointestinal haemorrhage	30.75	19.40	59	9286	147660	79587383
Hyperkalaemia	30.62	19.40	51	9294	114347	79620696
Blood pressure decreased	30.26	19.40	47	9298	99419	79635624
Pulmonary alveolar haemorrhage	30.08	19.40	18	9327	11439	79723604
Electrocardiogram QT prolonged	29.31	19.40	44	9301	90342	79644701
Prinzmetal angina	29.25	19.40	10	9335	1710	79733333
Ventricular fibrillation	28.17	19.40	26	9319	31900	79703143
Muscle haemorrhage	27.94	19.40	14	9331	6286	79728757
Fixed eruption	27.40	19.40	11	9334	2943	79732100
Hypoglycaemia	26.80	19.40	45	9300	101549	79633494
Haemorrhage intracranial	26.41	19.40	23	9322	26170	79708873
Pericardial haemorrhage	26.05	19.40	12	9333	4483	79730560
Prerenal failure	25.01	19.40	11	9334	3687	79731356
Fall	24.91	19.40	118	9227	487511	79247532
Chest pain	24.74	19.40	81	9264	282223	79452820
Brain stem stroke	24.03	19.40	7	9338	712	79734331
Coronary artery restenosis	23.67	19.40	8	9337	1321	79733722
Pain	23.32	19.40	29	9316	703773	79031270
Pemphigoid	23.03	19.40	17	9328	15298	79719745
Cardiac failure chronic	22.94	19.40	15	9330	11120	79723923
Immune thrombocytopenia	22.89	19.40	18	9327	17787	79717256
Lip swelling	22.78	19.40	26	9319	40885	79694158
Coagulation factor deficiency	22.77	19.40	5	9340	161	79734882
Rhabdomyolysis	22.45	19.40	42	9303	103089	79631954
Haemorrhage subcutaneous	22.26	19.40	11	9334	4798	79730245
Acute coronary syndrome	22.21	19.40	19	9326	21114	79713929
Angina unstable	21.88	19.40	17	9328	16510	79718533
Arthralgia	21.76	19.40	21	9324	571782	79163261
Circulatory collapse	21.07	19.40	24	9321	37644	79697399
Myocardial ischaemia	21.01	19.40	20	9325	25499	79709544
Hypovitaminosis	20.76	19.40	7	9338	1147	79733896
Pancytopenia	20.70	19.40	54	9291	165691	79569352
Inappropriate antidiuretic hormone secretion	20.49	19.40	20	9325	26293	79708750
Kounis syndrome	20.43	19.40	10	9335	4272	79730771
Weight increased	20.17	19.40	4	9341	277382	79457661
Anaemia	20.08	19.40	104	9241	444911	79290132

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C01DX16	CARDIOVASCULAR SYSTEM CARDIAC THERAPY VASODILATORS USED IN CARDIAC DISEASES Other vasodilators used in cardiac diseases
CHEBI has role	CHEBI:35620	vasodilator agents
CHEBI has role	CHEBI:79085	potassium channel agonist
MeSH PA	D000889	Anti-Arrhythmia Agents
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D018977	Micronutrients
MeSH PA	D014665	Vasodilator Agents
MeSH PA	D014803	Vitamin B Complex
MeSH PA	D014815	Vitamins

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Angina pectoris	indication	194828000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.97	acidic
pKa2	3.07	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Type	Activity value (-log[M])	Bioact source
ATP-sensitive inward rectifier potassium channel 11	Ion channel	Q14654	KCJ11_HUMAN	IC50	5.89	WOMBAT-PK
ATP-sensitive inward rectifier potassium channel 1	Ion channel	P48048	KCNJ1_HUMAN	IC50	5.95	WOMBAT-PK
Atrial natriuretic peptide receptor 1	Enzyme	P16066	ANPRA_HUMAN	EC50	7.20	WOMBAT-PK

External reference:

ID	Source
N0000167327	NUI
D01810	KEGG_DRUG
C0068700	UMLSCUI
CHEBI:31905	CHEBI
CHEMBL284906	ChEMBL_ID
DB09220	DRUGBANK_ID
D020108	MESH_DESCRIPTOR_UI
47528	PUBCHEM_CID
2411	IUPHAR_LIGAND_ID
4933	INN_ID
260456HAM0	UNII
31748	RXNORM
005831	NDDF
319304004	SNOMEDCT_US
395809002	SNOMEDCT_US

Pharmaceutical products:

None